CYD-4-61
Based on 1 Customer Validation
CYD-4-61 is a novel Bax activator used for breast cancer research. CYD-4-61 inhibits triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation. CYD-4-61 activates Bax protein to induce cytochrome c release and regulate apoptotic biomarkers, leading to cancer cell apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.41%
- CAS No.: 1425944-33-7
- Formule: C21H17N3O3
- Masse moléculaire:359.38
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
|
Bax |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MCF-10A | IC50 |
0.11 μM
Compound: CYD-4-61
|
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF-10A cells assessed as inhibition of cell viability after 72 hrs by MTT assay
|
[PMID: 33845235] |
| MCF7 | IC50 |
0.06 μM
Compound: CYD-4-61
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
|
[PMID: 33845235] |
| MDA-MB-231 | IC50 |
0.07 μM
Compound: CYD-4-61
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell viability after 72 hrs by MTT assay
|
[PMID: 33845235] |
CYD-4-61 (compound 49) (0-10 μM; 72 h) exhibits significantly improved antiproliferative activity with IC50s of 0.07 µM against triple-negative breast cancer MDA-MB-231 and 0.06 µM against ER-positive breast cancer MCF-7 cell lines, respectively[1].
CYD-4-61 (1 μM; 72 h) induces apoptosis among MCF-7 and MDA-MB-231 cells[1].
CYD-4-61 (5 μM and 10 μM; ) increases the level of cells with apoptotic bodies in MDA-MB-231 and MCF-7 cells[1].
CYD-4-61 (5 μM; 0-48 h) decreases the level of p-Bax, but increases the levle of total Bax protein, cytochrome c, and several protein markers related to apoptosis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF-10A, T47D, MCF-7, MDA-MB-231, and MDA-MB-468 cells
-
Concentration:0.1, 1, and 10 μM
-
Incubation Time:72 hours
-
Result:Inhibited triple-negative breast cancer MDA-MB-231 and ER-positive breast cancer MCF-7 cell lines proliferation and viability.
-
Cell Line:MCF-7 and MDA-MB-231 cells
-
Concentration:5 μM
-
Incubation Time:0, 6, 12, 24, and 48 hours
-
Result:Dose-dependently led to the upregulation of cleaved PARP-1, cleaved caspase 3, and downregulation of cyclin D1.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Triple-negative breast cancer MDA-MB-231 xenograft model in mice[1]
-
Dosage:2.5 mg/kg
-
Administration:Intraperitoneal injection; once daily for 7 consecutive days
-
Result:Significantly suppressed the growth of MDA-MB-231 tumors with an inhibition rate of 55%.
Chemical Information
-
CAS No. 1425944-33-7
-
Appearance Solid
-
Masse moléculaire 359.38
-
Formule C21H17N3O3
-
Color Light yellow to yellow
-
SMILES
NCCOC1=NC=CC=C1/C=C2C3=C(C4=C/2C=CC=C4)C=CC([N+]([O-])=O)=C3
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 20 mg/mL (55.65 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.7826 mL | 13.9128 mL | 27.8257 mL | 69.5642 mL |
| 5 mM | 0.5565 mL | 2.7826 mL | 5.5651 mL | 13.9128 mL | |
| 10 mM | 0.2783 mL | 1.3913 mL | 2.7826 mL | 6.9564 mL | |
| 15 mM | 0.1855 mL | 0.9275 mL | 1.8550 mL | 4.6376 mL | |
| 20 mM | 0.1391 mL | 0.6956 mL | 1.3913 mL | 3.4782 mL | |
| 25 mM | 0.1113 mL | 0.5565 mL | 1.1130 mL | 2.7826 mL | |
| 30 mM | 0.0928 mL | 0.4638 mL | 0.9275 mL | 2.3188 mL | |
| 40 mM | 0.0696 mL | 0.3478 mL | 0.6956 mL | 1.7391 mL | |
| 50 mM | 0.0557 mL | 0.2783 mL | 0.5565 mL | 1.3913 mL |
CYD-4-61 Related Classifications
HY-148368 Related Classifications
Powered by Bioz